MindTrace is a Pittsburgh, PA-based company established in 2020 as a spin-off from Carnegie Mellon University for the purpose of commercializing innovations to predict how neurosurgical interventions will affect patients’ minds. We are developing a novel, patent-pending software device that utilizes Artificial Intelligence/Machine Learning to integrate multiple sources of information to enable clinicians to more effectively plan neurosurgery in support of the best post-operative quality-of-life. MindTrace allows a clinical team to iterate on their surgical plan by exploring different paths of approach to a lesion, and the consequences of being more or less aggressive with the resections at the margin between lesion and healthy brain tissue. Put simply, patients want to be confident they will be the same person coming out of brain surgery as they were going into surgery—and surgeons want tools that support quantitative pre-operative surgical planning and evidence-based projections of post-operative function.